20-F: Adlai Nortye Ltd. Files 2024 Annual Report, Reveals Ongoing Net Losses and Going Concern Uncertainty

Adlai Nortye Ltd. reported continued net losses and substantial doubt about its ability to continue as a going concern in its 2024 annual report.

Summary

• Adlai Nortye Ltd., a Cayman Islands holding company operating primarily through subsidiaries in the US and China, filed its 2024 annual report on Form 20-F.
• The company is focused on developing innovative cancer therapies and has several drug candidates in various stages of clinical trials.
• Adlai Nortye reported a net loss of US$51.9 million for 2024, an improvement from the revised US$109.2 million loss in 2023.
• The company revised its 2023 financial statements to correct the accounting treatment for the sale of an exclusive option to enter into a license agreement.
• The company's cash and cash equivalents totaled US$60.9 million as of December 31, 2024.
• Management believes these funds, along with potential future NDA proceeds and financing activities, will be sufficient for at least the next 12 months.
• However, the company's auditors issued a going concern warning due to recurring losses and negative cash flows from operations.
• Adlai Nortye's lead product, AN2025, a pan-PI3K inhibitor, completed Phase III clinical trial enrollment in November 2023 and expects topline results in Q2 2025.
• The company has exclusive global rights to AN2025, licensed from Novartis.
• Other drug candidates, AN4005, AN8025, and AN9025, are in earlier stages of development.
• The company relies on third-party contract manufacturers for production and has licensing agreements with Novartis, Eisai, and Biotime for certain drug candidates.
• Adlai Nortye's ADSs are listed on the Nasdaq Stock Market under the symbol 'ANL'.

Sentiment

Score: 4

Explanation: While the decreased net loss and progress of AN2025 are positive, the going concern warning, continued losses, and dependence on external funding raise serious concerns about the company's long-term viability. The success of AN2025 is crucial for the company's future.

Positives

• Net loss decreased significantly year-over-year.
• Enrollment completed for the Phase III trial of lead product AN2025.
• AN2025 has the potential to be the first-to-market treatment for recurrent or metastatic HNSCC after anti-PD-1/PD-L1 therapy.
• AN4005 showed promising preliminary safety and efficacy results in Phase I trials.
• The company has established partnerships with major pharmaceutical companies like Novartis and Eisai.

Negatives

• The company continues to operate at a loss and has a going concern warning from its auditors.
• The company relies entirely on third-party manufacturers for drug production.
• No revenue generated from product sales to date.
• Material weaknesses in internal control over financial reporting were identified and are being remediated.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring losses and negative cash flows.
• Drug candidates may fail in clinical trials or fail to receive regulatory approval.
• Competition from larger pharmaceutical companies with greater resources is intense.
• The company relies on third-party manufacturers and licensors, which presents operational and supply chain risks.
• Changes in US and China regulations, particularly regarding overseas listings and data security, could negatively impact the company.
• The company's dual-class share structure gives significant control to the founder, potentially limiting the influence of other shareholders.

Future Outlook

The company expects its current cash reserves to be sufficient for at least the next 12 months, but acknowledges substantial doubt about its ability to continue as a going concern. They anticipate topline results for the AN2025 Phase III trial in Q2 2025 and plan to submit an NDA in the second half of the year if results are positive. IND filings for AN8025 and AN9025 are expected in mid-2025 and the second half of 2025, respectively. Proof-of-concept data for AN4005 and preliminary results for AN0025 trials are expected by the end of 2025.

Industry Context

The company operates in the highly competitive biotechnology and pharmaceutical industries, which are characterized by rapid technological change and significant investment in research and development. The immuno-oncology field, in particular, is experiencing intense competition, with several large biopharmaceutical companies developing therapies for similar indications. The regulatory landscape is also evolving, with new guidelines and expedited approval pathways being implemented in both the US and China.

Comparison to Industry Standards

• AN2025 is the only drug candidate currently in active Phase III clinical trials for recurrent or metastatic HNSCC after anti-PD-1/PD-L1 therapy, positioning it ahead of competitors like Innate Pharma S.A./AstraZeneca PLC's monalizumab, which was terminated in Phase II.
• AN4005, a small molecule PD-L1 inhibitor, offers potential advantages over existing monoclonal antibody therapies, such as oral administration and lower production costs, placing it in competition with early-stage candidates from companies like Maxinovel Pharmaceuticals Co., Ltd. and Incyte (whose INCB086550 was terminated but showed preliminary efficacy).
• AN9025, a pan-RAS(ON) inhibitor, targets a significant unmet need in oncology, with RAS mutations being prevalent drivers in various cancers. This puts the company in competition with other companies developing RAS inhibitors.

Management Changes

Related Party Transactions

• Non-revolving facility agreements were guaranteed by Mr. Yang Lu, the CEO and chairman.
• Share-based compensation was granted to key management personnel.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and the risk of losing their investment if the company is unable to achieve profitability or continue as a going concern.
• Employees may be impacted by the company's financial uncertainty and potential need for restructuring or downsizing if additional funding cannot be secured.
• The company's ability to attract and retain qualified personnel may be affected by its financial performance and the uncertainty surrounding its future.

Next Steps

• Release topline results for AN2025 Phase III trial in Q2 2025.
• Submit NDA for AN2025 in the second half of 2025, pending positive trial results.
• File IND applications for AN8025 and AN9025 in mid-2025 and the second half of 2025, respectively.
• Obtain proof-of-concept data for AN4005 and preliminary results for AN0025 trials by the end of 2025.
• Continue remediation efforts to address material weaknesses in internal control over financial reporting.

Key Dates

Keywords

oncology, biotechnology, cancer therapy, drug development, clinical trials, immunotherapy, PI3K inhibitor, PD-L1 inhibitor, HNSCC, Nasdaq, IFRS, SEC, China, United States, licensing, Novartis, Eisai, Biotime